Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review

Abstract Objective To evaluate the long-term safety (≥12 months) of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) or its receptor in migraine prevention by synthesising evidence from clinical trials and real-world studies. We focus on drug discontinuation due to a...

全面介紹

書目詳細資料

Principais autores:	Carolin Luisa Hoehne, Lucas Hendrik Overeem, Margarita Sanchez-Del-Rio, Christiana Deligianni, Raquel Gil-Gouveia, Jan Versijpt, Faisal Mohammad Amin, Christian Lampl, Kristina Ryliskiene, Erling Tronvik, Gianluca Coppola, Philip R. Holland, Antoinette MaassenVanDenBrink, Paolo Martelletti, Uwe Reuter, on behalf of the European Headache Federation, EHF
格式:	Artigo
語言:	Inglês
出版:	BMC 2026-01-01
叢編:	The Journal of Headache and Pain
主題:	Migraine Galcanezumab Fremanezumab Erenumab Eptinezumab Long-term safety
在線閱讀:	https://doi.org/10.1186/s10194-025-02256-0
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!